Evidence map›Paper›PMID 29089594›Full record

ArticleThe Journal of antibiotics2018

Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions.

Yoshinari Wakiyama, Ko Kumura, Eijiro Umemura, Satomi Masaki, Kazutaka Ueda, Yasuo Sato, Yoko Hirai, Yoshio Hayashi, Keiichi Ajito

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yoshinari WakiyamaPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Ko KumuraPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Eijiro UmemuraPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Satomi MasakiPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Kazutaka UedaPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Yasuo SatoPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Yoko HiraiPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Yoshio HayashiDepartment of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences 1, Tokyo, Japan.
Keiichi AjitoPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Tokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to modify lincomycin at the C-6 and C-7 positions, we prepared target molecules, which have substituted pipecolinic acid at the 6-amino group and a para-substituted phenylthio group at the C-7 position, in application of palladium-catalyzed cross-coupling as a key reaction. As the result of structure-activity relationship (SAR) studies at the 6-position, analogs possessing 4'-cis-(cyclopropylmethyl)piperidine showed significantly strong antibacterial activities against Streptococcus pneumoniae and Streptococcus pyogenes with an erm gene. On the basis of SAR, we further synthesized novel analogs possessing 4'-cis-(cyclopropylmethyl)piperidine by transformation of a C-7 substituent. Consequently, novel derivatives possessing a para-heteroaromatic-phenylthio group at the C-7 position exhibited significantly strong activities against S. pneumoniae and S. pyogenes with an erm gene even when compared with those of telithromycin. Finally, in vivo efficacy of selected two derivatives was evaluated in a rat pulmonary infection model with resistant S. pneumoniae with erm + mef genes. One of them exhibited strong and constant in vivo efficacy in this model, and both compounds showed strong in vivo efficacy against resistant S. pneumoniae with a mef gene.

Indexed as

AnimalsAnti-Bacterial AgentsBacterial ProteinsDrug Resistance, BacterialKetolidesLincomycinMembrane ProteinsMicrobial Sensitivity TestsNeutropeniaPneumonia, PneumococcalRatsStreptococcus pneumoniaeStreptococcus pyogenesStructure-Activity RelationshipAnti-Bacterial AgentsBacterial ProteinsKetolidesLincomycinMefA protein, StreptococcusMembrane Proteinstelithromycin

Identifiers

PMID29089594
OpenAlexW2765885198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.